A- A A+

Effects of All-Oral Anti-Viral Therapy on HVPG and Systemic Hemodynamics in Patients With Hepatitis C Virus-Associated Cirrhosis

Lens, Sabela et al.

Gastroenterology , Volume 153 , Issue 5 , 1273 - 1283.e1

Abstract

https://www.ncbi.nlm.nih.gov/pubmed/28734831

Predicting Early Viral Control under Direct-Acting Antiviral Therapy for Chronic Hepatitis C Virus Using Pretreatment Immunological Markers.

Hutchinson JA, Weigand K, Adenugba A, Kronenberg K, Haarer J, Zeman F, Riquelme P, Hornung M, Ahrens N, Schlitt HJ, Geissler EK, Werner JM.

Front Immunol. 2018 Feb 7;9:146. doi: 10.3389/fimmu.2018.00146.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5808305/

Hepatitis B Reactivation With Hepatitis C Treatment: Bringing Some Clarity to the Black Box

Ma, Ann T.Feld, Jordan J. et al.

Gastroenterology. 2018 Feb 6. pii: S0016-5085(18)30161-6. doi: 10.1053/j.gastro.2018.02.005.

http://www.gastrojournal.org/article/S0016-5085(18)30161-6/fulltext

Predictors of functional benefit of hepatitis C therapy in a 'real-life' cohort.

Steinebrunner N, Stein K, Sandig C, Bruckner T, Stremmel W, Pathil A.

World J Gastroenterol. 2018 Feb 21;24(7):852-861. doi: 10.3748/wjg.v24.i7.852.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5807943/

Resistance analysis of genotype 3 HCV indicates subtypes inherently resistant to NS5A inhibitors.

Smith D, Magri A, Bonsall D, Ip CL, Trebes A, Brown A, Piazza P, Bowden R, Nguyen D; STOP-HCV Consortium, Ansari MA, Simmonds P, Barnes E.

Hepatology. 2018 Feb 9. doi: 10.1002/hep.29837.

Abstract

https://www.ncbi.nlm.nih.gov/pubmed/29425396

Age-Specific Global Prevalence of Hepatitis B, Hepatitis C, HIV, and Tuberculosis Among Incarcerated People: A Systematic Review.

Kinner SA, Snow K, Wirtz AL, Altice FL, Beyrer C, Dolan K.

J Adolesc Health. 2018 Mar;62(3S):S18-S26. doi: 10.1016/j.jadohealth.2017.09.030.

http://www.jahonline.org/article/S1054-139X(17)30497-4/fulltext

Hepatitis C infection, related services, and barriers to HCV treatment among drug users in methadone maintenance treatment (MMT) clinics in Shanghai, China.

Li ZB, Zhang L, Wang J, Huang LP, Zhou ZR, Cao YN, Zhao M, Du J.

Harm Reduct J. 2017 Nov 2;14(1):71. doi: 10.1186/s12954-017-0197-3.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5667515/

Lymphoproliferative disease with mixed cryoglobulinemia and hyperviscosity syndrome in an HIV-infected patient: HCV is the only culprit.

Zanotti P, Izzo I, Casari S, Cattaneo C, Zaltron S, Spinetti A, Odolini S, Chirico C, Grecchi C, Festa E, Castelli F.

New Microbiol. 2017 Oct;40(4):289-290.

http://www.newmicrobiologica.org/PUB/allegati_pdf/2017/4/289.pdf

The patient-provider relationship is associated with hepatitis C treatment eligibility: A prospective mixed-methods cohort study.

Rogol SS, Arnold RM, Chapko M, et al.

PLoS ONE. 2016; 11(2): e0148596. doi:10.1371/journal.pone.0148596.

http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0148596

Island will Hepatitis C ausrotten

Reykjavik – Die isländischen Gesundheitsbehörden haben begonnen, allen Einwohnern des Landes, die mit Hepatitis C infiziert sind, eine kostenlose Behandlung mit direkt antiviral wirksamen Medikamenten (DAA) anzubieten. Nach einer Studie im Journal of Internal Medicine (2018; doi: 10.1111/joim.12740) wurde möglicherweise bereits die Hälfte aller Infizierten behandelt. Die Behandlungsergebnisse entsprechen den Erwartungen. (aerzteblatt.de, 08.03.2018)

https://www.aerzteblatt.de/nachrichten/91684/Island-will-Hepatitis-C-ausrotten

The Egyptian hepatitis C programme: a model of HCV treatment intervention?

Lemoine, M. et al.

Journal of Hepatology , Volume 0 , Issue 0 , doi.org/10.1016/j.jhep.2018.01.021

http://www.journal-of-hepatology.eu/article/S0168-8278(18)30068-0/fulltext

Erfolgreiche Nierentransplantation mit Hepatitis C infizierter Organspende

Baltimore – Eine Behandlung mit direkt antiviralen Medikamenten (DAA) kann die Empfänger von Organen infizierter Spender vor einer Hepatitis C schützen. Dies zeigen die Ergebnisse einer Pilotstudie in den Annals of Internal Medicine (2018; doi: 10.7326/M17-2871). (aerzteblatt.de, 07.03.2018)

https://www.aerzteblatt.de/nachrichten/91632/Erfolgreiche-Nierentransplantation-mit-Hepatitis-C-infizierter-Organspende

Needle and syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: findings from a Cochrane Review and meta-analysis.

Platt, L., Minozzi, S., Reed, J., Vickerman, P., Hagan, H., French, C., Jordan, A., Degenhardt, L., Hope, V., Hutchinson, S., Maher, L., Palmateer, N., Taylor, A., Bruneau, J., and Hickman, M. (2018)

Addiction, 113: 545563. doi: 10.1111/add.14012.

http://onlinelibrary.wiley.com/doi/10.1111/add.14012/full

Elbasvir/Grazoprevir and Sofosbuvir for HCV Genotype 3 Infection With Compensated Cirrhosis: A Randomized Trial.

Foster GR, Agarwal K, Cramp ME, Moreea S, Barclay S, Collier J, Brown AS, Ryder SD, Ustianowski A, Forton DM, Fox R, Gordon F, Rosenberg WM, Mutimer DJ, Du J, Gilbert CL, Asante-Appiah E, Wahl J, Robertson MN, Barr E, Haber B.

Hepatology. 2018 Feb 23. doi: 10.1002/hep.29852.

Abstract

https://www.ncbi.nlm.nih.gov/pubmed/29473975

Hepatitis C virus cure does not impact kidney function decline in HIV co-infected patients.

Rossi C, Saeed S, Cox J, Vachon ML, Martel-Laferrière V, Walmsley SL, Cooper C, Gill MJ, Hull M, Moodie EEM, Klein MB; Canadian Co-Infection Cohort Investigators.

AIDS. 2018 Jan 23. doi: 10.1097/QAD.0000000000001750.

Abstract

https://www.ncbi.nlm.nih.gov/pubmed/29369156

Aidshilfe NRW. HIV UND HEPATITIS 2017 – Fachtagsdokumentation, 10. August 2017

(Herausgeber: Aidshilfe NRW e.V., 2018)

http://www.landesstellesucht-nrw.de/tl_files/images/pages/News/2017_fachtag_hiv_hep_dokumentation.pdf

RKI. Ratgeber für Ärzte zu Hepatitis C aktualisiert

Der RKI-Ratgeber für Ärzte zum Thema Hepatitis C ist aktualisiert worden. Der Ratgeber gibt − wie alle Veröffentlichungen der Ratgeber-Reihe - einen Überblick zu Erreger, Vorkommen, Reservoir, Infektionsweg, Inkubationszeit, Dauer der Ansteckungsfähigkeit, Klinische Symptomatik, Diagnostik, Therapie sowie Präventiv- und Bekämpfungsmaßnahmen. Hepatitis C ist eine weltweit beim Menschen vorkommende, durch Hepatitis-C-Viren (HCV) ausgelöste Leberentzündung. Ohne Therapie nimmt die Infektion in 50 bis 85% der Fälle einen chronischen Verlauf, der nach Jahrzehnten eine Leberzirrhose oder ein Leberzellkarzinom verursachen kann. Die Herausgabe der Ratgeber für Ärzte erfolgt auf der Grundlage des Infektionsschutzgesetzes. Praktisch bedeutsame Angaben zu wichtigen Infektionskrankheiten sollen aktuell und konzentriert der Orientierung dienen. Die Ratgeber werden in Zusammenarbeit mit den Nationalen Referenzzentren, Konsiliarlaboren sowie weiteren Experten erarbeitet. (Robert Koch Institut, Berlin, 01.02.2018)

https://www.rki.de/DE/Content/Infekt/EpidBull/Merkblaetter/Ratgeber_HepatitisC.html

Hepatitis B Core-related Antigen (HBcrAg): An Emerging Marker for Chronic Hepatitis B Virus Infection

L.-Y. Mak; D. K.-H. Wong; K.-S. Cheung; W.-K. Seto; C.-L. Lai; M.-F. Yuen

Aliment Pharmacol Ther. 2018;47(1):43-54. 

https://www.medscape.com/viewarticle/890298

TRAINING MANUAL FOR TREATMENT ADVOCATES: Hepatitis C Virus and Coinfection with HIV

Treatment Action Group 2018

ISBN 978-0-9983966-5-1

http://www.treatmentactiongroup.org/sites/default/files/HCV_curriculum_final_english.pdf

Rare Clinically Significant Hepatic Events and Hepatitis B Reactivation Occur More Frequently Following Rather Than During Direct-acting Antiviral Therapy for Chronic Hepatitis C

Data From a National US Cohort

M. Serper; K. A. Forde; D. E. Kaplan, J Viral Hepat. 2018;25(2):187-197. 

https://www.medscape.com/viewarticle/892001

Hepatitis C-related cryoglobulinemic neuropathy: potential role of oxcarbazepine for pain control.

Moretti R, Caruso P, Dal Ben M, Gazzin S, Tiribelli C.

BMC Gastroenterol. 2018 Jan 25;18(1):19. doi: 10.1186/s12876-018-0751-9.

https://bmcgastroenterol.biomedcentral.com/articles/10.1186/s12876-018-0751-9

Hepatitis. ECHO: the hub & spoke program connecting primary care with expert centres

Earlier this year, the World Health Organization reported that its goal of eliminating viral hepatitis as a global public health threat by 2030 has come well within reach, with 194 governments committed to hepatitis elimination; drastic price reductions in medicines through the use of generics; and effective harm reduction, screening, and treatment approaches currently available. Close to 3 million people have been able to access treatment for hepatitis C over the past 2 years, and 2.8 million people started lifelong treatment for hepatitis B in 2016 alone. Yet yearly rates of new infections continue to increase worldwide. Rapid global scale-up of screening, prevention, and treatment services – putting knowledge of those services into the hands of the frontline healthcare providers who serve communities and patients most at risk – is crucial if the dream of eliminating hepatitis is ever to be fully realized.1

Project ECHO (Extension for Community Healthcare Outcomes) is an innovative tool for the dissemination of medical knowledge to providers in medically underserved areas, which has the potential to tip the scales of worldwide efforts to halt the advance of hepatitis. It is not “telemedicine,” wherein a specialist assumes the care of a patient; rather, it enables primary care providers to care more effectively for patients in their own communities. (EASL-ILF, Newsletter #3, Februar 2018)

https://easl-ilf.org/news/echo-the-hub/

Strategies to control HIV and HCV in methadone maintenance treatment in Guangdong Province, China: a system dynamic modeling study.

Zou X, Xu Y, Chen W, Xia Y, Liu Y, Gong C, Ling L.

Subst Abuse Treat Prev Policy. 2018 Jan 10;13(1):1. doi: 10.1186/s13011-017-0140-3.

https://substanceabusepolicy.biomedcentral.com/articles/10.1186/s13011-017-0140-3

Rationale, design, and methodology of a trial evaluating three models of care for HCV treatment among injection drug users on opioid agonist therapy.

Akiyama MJ, Agyemang L, Arnsten JH, Heo M, Norton BL, Schackman BR, Linas BP, Litwin AH.

BMC Infect Dis. 2018 Feb 9;18(1):74. doi: 10.1186/s12879-018-2964-5.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5807730/

All-oral DAA therapy against HCV in HIV/HCV-coinfected subjects in real-world practice: Madrid-CoRe Findings.

Berenguer, J., Gil-Martin, Á., Jarrin, I., Moreno, A., Dominguez, L., Montes, M., Aldámiz-Echevarría, T., Téllez, M. J., Santos, I., Benitez, L., Sanz, J., Ryan, P., Gaspar, G., Alvarez, B., Losa, J. E., Torres-Perea, R., Barros, C., San Martin, J. V., Arponen, S., de Guzmán, M. T., Monsalvo, R., Vegas, A., Garcia-Benayas, M. T., Serrano, R., Gotuzzo, L., Menendez, M. A., Belda, L. M., Malmierca, E., Calvo, M. J., Cruz-Martos, E. and González-García, J. J. (),

Hepatology. Accepted Author Manuscript. doi:10.1002/hep.29814

Abstract

http://onlinelibrary.wiley.com/doi/10.1002/hep.29814/abstract

Sofosbuvir-Based Direct-Acting Antiviral Therapies for HCV in People Receiving Opioid Substitution Therapy: An Analysis of Phase 3 Studies.

Grebely J, Feld JJ, Wyles D, Sulkowski M, Ni L, Llewellyn J, Mir HM, Sajed N, Stamm LM, Hyland RH, McNally J, Brainard DM, Jacobson I, Zeuzem S, Bourlière M, Foster G, Afdhal N, Dore GJ.

Open Forum Infect Dis. 2018 Feb 9;5(2):ofy001. doi: 10.1093/ofid/ofy001.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5808802/